Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9755705 | 0.76 | ESR1 (0.47) | ALDH1A1HTR2AHTR2CMEN1KMT2A | |
| SCHEMBL17548404 | 0.75 | HTR2A (0.48) | ALDH1A1HTR2AHTR2C | |
| SCHEMBL375036 | 0.74 | OPRM1 (0.53) | ALDH1A1MEN1KMT2A | |
| SCHEMBL7915425 | 0.72 | ESR1 (0.53) | ALDH1A1HTR2AHTR2CMEN1KMT2A | |
| SCHEMBL13024122 | 0.70 | ESR1 (0.60) | ALDH1A1HTR2AHTR2CMEN1KMT2A | |
| SCHEMBL4553629 | 0.69 | ALDH1A1 (0.72) | ALDH1A1PAX8 | |
| SCHEMBL23828847 | 0.67 | DRD4 (0.46) | ALDH1A1MEN1KMT2APAX8 | |
| SCHEMBL4884271 | 0.67 | ESR1 (0.55) | ALDH1A1HTR2AHTR2CMEN1KMT2A | |
| SCHEMBL23828849 | 0.66 | SLC2A1 (0.50) | ALDH1A1MEN1KMT2APAX8 | |
| SCHEMBL6487558 | 0.66 | KDM4E (0.63) | ALDH1A1MEN1KMT2APAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377711-B2 | Cannabinoid type 1 receptor modulators | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2019-08-13 | — | — | US | disclosed |
| US-20180118681-A1 | CANNABINOID TYPE 1 RECEPTOR MODULATORS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2018-05-03 | — | — | US | disclosed |
| US-20180118681-A1 | CANNABINOID TYPE 1 RECEPTOR MODULATORS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2018-05-03 | — | — | US | disclosed |
| WO-2016029310-A1 | CANNABINOID TYPE 1 RECEPTOR MODULATORS | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118681-A1 | CANNABINOID TYPE 1 RECEPTOR MODULATORS | CNR1, CNR2, GPR18 | ALDH1A1 1498/4885HTR2A 50/4885HTR2C 37/4885 |
| US-10377711-B2 | Cannabinoid type 1 receptor modulators | CNR1, CNR2, GPR18 | ALDH1A1 1498/4885HTR2A 50/4885HTR2C 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.